UAEM Logo
Universities Allied for Essential Medicines

Site search

News Categories

News Archive

Many of the world's most important medicines and public health devices are wholly or partly developed in academic laboratories. Their accessibility to those living in poor nations is profoundly affected by the research, licensing and patenting decisions made by universities.

As members of these institutions of higher learning, we believe that universities have an opportunity and a responsibility to improve global access to public health goods--particularly those they have helped develop.


Recent News...

Please Join Us in D.C. July 30th

UAEM will be hosting a reception and fundraiser in Washington, DC on Wednesday July 30th. There will be live music and great company. We hope you can join us. Tickets and details are available here.

IGWG Statement by Ethan Guillen of Universities Allied for Essential Medicines

May 3, 2008

Today Ethan Guillen, Executive Director of Universities Allied for Essential Medicines (www.essentialmedicine.org), issued the following statement on the World Health Organization Intergovernmental Working Group in Public Health, Innovation and Intellectual Property:

“We were pleased to see the advancement in the negotiations of important issues like technology transfer that promotes innovation of and access to medicines for the developing world. We’re hopeful that consensus recommendations on open licensing and other technology transfer provisions agreed to during this round will send a strong message to universities: they need to adopt policies that will free up the tools of innovation and make medicines discovered on campuses available at low-cost in the developing world.

“However, the lack of bold commitment by most of the rich countries is surprising to say the least. That there had to be stiff negotiations on the idea that the cost of medicines impedes access in the developing world makes you wonder if some negotiators hadn’t noticed that busloads of American retirees who have to hop across the U.S. border to Canada to get drugs they can afford. New incentive mechanisms are obviously necessary to promote R&D for medicines that don’t have a market in the developed world.

“Universities can lend a credible voice to the continuing effort but sadly, haven’t yet positively engaged. Given that the process will now continue beyond the November elections in the U.S., they now have a renewed opportunity to work toward a stronger final strategy.”

Statement of Churches (the Delegation UAEM is on), MSF, KEI, HAI

Today, NGOs at the WHO IGWG had an opportunity to give statements to the plenary session. Below are a number of statements made by civil society organizations, including the collaborative statement of the Churches delegation in which we participated.

Joint Statement of Churches Delegation

This statement was written by delegation members from Essential Action,
Third World Network, and Universities Allied for Essential Medicines.

1 May 2008

Statement of CMC - Churches’ Action for Health at WHO IGWG II bis

My name is Sarah Rimmington, and I am speaking on behalf of the CMC
Churches’ Action for Health delegation. We are pleased to address the
WHO Intergovernmental Working Group (IGWG) on public health, innovation
and intellectual property.

Medical research and development breakthroughs have made the world a
better and healthier place, thus serving the mission of justice, peace
and integrity of creation. Vaccines, antibiotics and drugs for
conditions such as HIV/AIDS have kept countless millions alive and
reduced untold suffering. Read more »

Prizes and Parasites at IGWG

Prizes and Parasites

One subject attracting a great deal of attention this week at the IGWG meeting in Geneva is that of prizes as an alternative incentive approach for neglected disease R&D, with multiple different examples of prize proposals on the table. In following the negotiations, it has been have noted that there have been questions about the relative difficulty of various research programs discussed in the prize proposals that have been put forward. Specifically, the proposal on Chagas disease has been questioned on the grounds that it is too difficult of a problem, citing the lack of success to date. While it is indeed true that we currently lack effective treatments and vaccines for Chagas - and, in fact, for the majority of parasitic diseases - there is no a reason to think that these diseases are insoluble. We are aggressively pursuing treatment for extremely complex diseases such as Alzheimer’s, and, despite the enormous amounts of money being thrown at this disease, many doubt that a cure or even an effective treatment will ever be found. Parasitic diseases, while not simple to address, should in no way be thought of in the same category of complexity as diseases such as Alzheimer’s - a disease to which we devote many times the amount of resources. In fact, given the relatively tiny amount of funding put towards parasitic diseases thus far, it is somewhat amazing that we have made as much progress as we have. Read more »